Skip to content
Home/Companies/Healthcare / Biotech/Vivet
Vivet

Vivet

Healthcare / Biotech·France·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Vivet?

Vivet is currently owned by Eurazeo through Kurma Biofund III (2017 vintage), since 2019.

Hand-verified · updated 2026-04-21

Eurazeo
Investor
Eurazeo
Kurma Biofund III · 2017 · Healthcare

Key facts

HQFrance
SectorHealthcare / Biotech
Websitewww.vivet-therapeutics.com

More from Kurma Biofund III

Other portfolio companies in the same fund.

ImCheck
ImCheck
Exited 2025
BiotechFrance· 2020
to
Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2019
to
Ermium
Ermium
Active
BiotechFrance· 2019
IO Biotech
IO Biotech
Active
BiotechDenmark· 2019
Pharvaris
Pharvaris
Active
BiotechNetherlands· 2019
Orphazyme
Orphazyme
Active
BiotechDenmark· 2017

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Vivet

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Vivet?

0 strategic and 120financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Vivet.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue